Adela

Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test. The company’s genome-wide methylome enrichment platform captures information from small quantities of cell-free DNA and applies machine learning to detect and classify underlying disease. The platform is unique in its ability to efficiently capture broad genomic information and preserve it during sequencing. Adela’s technology does not require bisulfite conversion, which is a chemical treatment that causes loss of valuable genomic material. The technology is initially being developed for use across the cancer continuum for detection, diagnosis, and management, and in the future will be applied to other conditions beyond cancer.